SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Genethera Inc – ‘10-K’ for 12/31/19 – ‘EX-32.2’

On:  Wednesday, 6/10/20, at 3:31pm ET   ·   For:  12/31/19   ·   Accession #:  1199835-20-136   ·   File #:  0-27237

Previous ‘10-K’:  ‘10-K’ on 2/27/20 for 12/31/18   ·   Next:  ‘10-K/A’ on 9/21/20 for 12/31/19   ·   Latest:  ‘10-K/A’ on 2/1/23 for 12/31/21   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/10/20  Genethera Inc                     10-K       12/31/19   42:2.1M                                   Highland Services/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Genethera, Inc. 10-K                                HTML    453K 
 2: EX-31.1     Certifications of Principal Executive Officer       HTML     21K 
                Pursuant to Section 302 of the Sarbanes-Oxley Act                
                of 2002                                                          
 3: EX-31.2     Certifications of Principal Financial and           HTML     21K 
                Accounting Officer Pursuant to Section 302 of the                
                Sarbanes-Oxley Act of 2002                                       
 4: EX-32.1     Certification of Principal Executive Officer        HTML     16K 
                Pursuant to Section 906 of the Sarbanes-Oxley Act                
                of 2002                                                          
 5: EX-32.2     Certification of Principal Financial and            HTML     16K 
                Accounting Officer Pursuant to Section 906 of the                
                Sarbanes-Oxley Act of 2002                                       
39: R1          Document and Entity Information                     HTML     56K 
23: R2          Consolidated Balance Sheets                         HTML     87K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     36K 
27: R4          Consolidated Statements of Operations               HTML     53K 
38: R5          Consolidated Statements of Stockholders' Equity     HTML     60K 
                (Deficit)                                                        
22: R6          Consolidated Statements of Cash Flows               HTML     83K 
17: R7          Organization and nature of operations and summary   HTML     51K 
                of significant accounting policies                               
26: R8          Going Concern                                       HTML     19K 
40: R9          Accrued expenses                                    HTML     20K 
37: R10         Related party transactions                          HTML     22K 
33: R11         Other Income and Accrued Liabilities                HTML     22K 
13: R12         Convertible notes payable                           HTML     23K 
25: R13         Shareholders' equity                                HTML     40K 
36: R14         Commitments and Contingencies                       HTML     39K 
32: R15         Income Taxes                                        HTML     31K 
12: R16         Subsequent events                                   HTML     19K 
24: R17         Organization and nature of operations and summary   HTML    101K 
                of significant accounting policies (Policies)                    
35: R18         Accrued expenses (Tables)                           HTML     20K 
34: R19         Other Income and Accrued Liabilities (Tables)       HTML     21K 
15: R20         Income Taxes (Tables)                               HTML     26K 
21: R21         Organization and nature of operations and summary   HTML     19K 
                of significant accounting policies (Details                      
                Narrative)                                                       
42: R22         Going Concern (Details Narrative)                   HTML     19K 
29: R23         Accrued expenses (Details)                          HTML     25K 
14: R24         Related party transactions (Details Narrative)      HTML     32K 
20: R25         Other Income and Accrued Liabilities (Details)      HTML     16K 
41: R26         Shareholders' equity (Details Narrative)            HTML     36K 
28: R27         Income Taxes (Details)                              HTML     22K 
16: R28         Income Taxes (Details 2)                            HTML     24K 
30: XML         IDEA XML File -- Filing Summary                      XML     67K 
19: EXCEL       IDEA Workbook of Financial Reports                  XLSX     44K 
 6: EX-101.INS  XBRL Instance -- gnth-20191231                       XML    409K 
 8: EX-101.CAL  XBRL Calculations -- gnth-20191231_cal               XML     84K 
 9: EX-101.DEF  XBRL Definitions -- gnth-20191231_def                XML    167K 
10: EX-101.LAB  XBRL Labels -- gnth-20191231_lab                     XML    391K 
11: EX-101.PRE  XBRL Presentations -- gnth-20191231_pre              XML    300K 
 7: EX-101.SCH  XBRL Schema -- gnth-20191231                         XSD     69K 
31: ZIP         XBRL Zipped Folder -- 0001199835-20-000136-xbrl      Zip     60K 


‘EX-32.2’   —   Certification of Principal Financial and Accounting Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Tannya L. Irizarry, the Interim Chief Financial Officer of GeneThera, Inc. (the “Company”), DOES HEREBY CERTIFY that:

 

1.       The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the “Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

2.       Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 10th day of June, 2020.

 

  /s/ Tannya L. Irizarry
  Tannya L. Irizarry
Interim Chief Financial Officer
(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906 has been provided to GeneThera, Inc. and will be retained by GeneThera, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

The foregoing certification is being furnished to the Securities and Exchange Commission pursuant to § 18 U.S.C. Section 1350. It is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 C: 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:6/10/20
For Period end:12/31/19NT 10-K
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/25/20  SEC                               UPLOAD10/27/20    2:39K  Genethera Inc.
 9/18/20  SEC                               UPLOAD10/27/20    2:43K  Genethera Inc.
Top
Filing Submission 0001199835-20-000136   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 10:28:29.1am ET